Loading…
Loading…
FRX (Forest Road Acquisition Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
No price history for this window.
FRX does not currently pay a dividend.
See exactly how FRX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FRX and 80,000+ other tickers.
Forest Road Acquisition Corp., established in 2020 and headquartered in New York, New York, is focused on identifying and executing a strategic consolidation with one or more companies. The firm aims to complete various corporate transactions, including mergers, exchanges of capital stock, asset acquisitions, stock purchases, or other forms of corporate restructuring, specifically targeting the technology, media, and telecommunications sectors.
Fennec Pharmaceuticals Inc. (TSE: FRX - Get Free Report) passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of C$13.94 and traded as high as C$14.65. Fennec Pharmaceuticals shares last traded at C$14.65, with a volume of 412 shares. Fennec Pharmaceuticals Trading Up 3.0% The company has
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to purchase an aggregate of 859 shares. The Stock Options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript